Read more
2:48 PM · 19 December 2023

CureVac loses 34% as German court quashes company's patent

CureVac
Stocks
CVAC.US, CureVac N.V.
-
-

CureVac (CVAC.US) loses more than 30% today after a German court quashed a company's patent. As Reuters analysis reports, the patent in question is one of several intellectual property titles that CureVac claims were infringed in ongoing legal proceedings. The patent was also the basis of a patent violation lawsuit by CureVac against its market rival and mRNA vaccines producer, BioNTech (BNTX.US), in a blow to CureVac's claims for a share in billions of euros in COVID-19 vaccine revenues. As presiding judge in Germany's patent court, said in his ruling after a hearing, the patent is now invalid for the Germany territory. Biontech's shares are up 2% today. CureVac'smRNA-based COVID-19 vaccine didn't bring any significant cash from sales. At the same time, BioNTech / Pfizer collaboration made more than $40 billion in combined vaccines sales in 2021 and 2022. 

Source: xStation5

18 November 2025, 6:50 PM

Daily summary: Wall Street tries to rebound 📈Amazon and Microsoft under pressure of Rotschild & Co Redburn

18 November 2025, 4:13 PM

Home Depot shares slide 4% on outlook cut citing weakening consumption 📉

18 November 2025, 3:17 PM

US Open: Wall Street indices under continued selling pressure 📌Technology stocks slide

18 November 2025, 2:22 PM

Clouflare shares down in pre-market amid internet outage📌

Join over 2 000 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits